title: Insulin glulisine. Aventis Pharma.
abstract: Aventis Pharma (formerly Hoechst Marion Roussel) is developing insulin glulisine, a fast-acting insulin analog, for the potential treatment of hyperglycemia in both type 1 and 2 diabetes. Aventis has submitted an NDA and an MAA to the FDA and the EMEA, respectively.
authors.affiliation: Istituto di Chimica Farmaceutica e Tossicologica, University of Milan, Viale Abruzzi 42, 20131 Milan, Italy. daniela.barlocco@unimi.it
authors.forename: Daniela
authors.initials: D
authors.lastname: Barlocco
mesh_terms: D000818:Animals; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007328:Insulin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; C479079:insulin glulisine